Acelyrin, Inc.
SLRN · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.02 | 0.06 | -0.01 |
| FCF Yield | -15.67% | -39.02% | -16.06% | -11.20% |
| EV / EBITDA | -3.29 | -8.62 | -6.44 | -3.16 |
| Quality | ||||
| ROIC | -14.49% | -18.45% | -10.24% | -16.34% |
| Gross Margin | 0.00% | 50.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.70 | 1.54 | 1.62 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 699,219.07% | 699,219.07% | 549,486.47% | 549,486.47% |
| Free Cash Flow Growth | 67.98% | -53.89% | -67.90% | 17.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.88 | 2.39 | 4.79 | 1.37 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 5,382.63 | -14,900.94 | -31,594.66 |